Advertisement

Bronchiolitis of immune checkpoint inhibitor therapy-related pneumonitis

Published:September 22, 2022DOI:https://doi.org/10.1016/j.amjms.2022.09.009
      A 77-year-old man was diagnosed with lung adenocarcinoma and presented with bone and liver metastases (cT1bN2M1c; stage IVB). The driver mutations were negative, and the programmed cell death ligand 1 tumor proportion score was 80%. He underwent immune-checkpoint inhibitor (ICI) therapy (pembrolizumab 200 mg/m2) every three weeks. Pembrolizumab immunotherapy was administered for a total of 35 cycles, all lung lesions disappeared (Fig. 1A), and the therapeutic outcome was considered a complete response.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of the Medical Sciences
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Naidoo J
        • Wang X
        • Woo KM
        • et al.
        Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy.
        J Clin Oncol. 2017; 35: 709-717
        • Delaunay M
        • Cadranel J
        • Lusque A
        • et al.
        Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients.
        Eur Respir J. 2017; 501700050